Loading stock data…
HROW
$40.90+0.37 (+0.91%)
Market ClosedLast close May 1
Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Harrow, Inc. in the Healthcare sector is trading at $40.90. The stock is currently 25% below its 52-week high of $54.85, remaining 1.1% below its 200-day moving average. Technical signals show neutral RSI of 66 and bullish MACD crossover, explaining why HROW maintains its current current market pressure. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Overbought levels (RSI 66) — risk of consolidation or pullback
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$40.90
Potential Upside
5%
Whystock Fair Value$42.95
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States. It operates through Branded and ImprimisRx segments. The company offers Imprimis...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.46B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.31
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-9.80%
Volume
Today's trading volume
469,050
Recent News
Is Harrow, Inc. (HROW) A Good Stock To Buy Now?
Is HROW a good stock to buy? We came across a bullish thesis on Harrow, Inc. on MVC Investing’s Substack by M. V. Cunha. In this article, we will summarize the bulls’ thesis on HROW. Harrow, Inc.’s share was trading at $40.50 as of April 20th. HROW’s trailing and forward P/E were 9.64 and 74.07 respectively according to Yahoo Finance. Harrow, […]
Top Growth Companies With Strong Insider Ownership April 2026
Over the last 7 days, the United States market has risen by 4.2%, contributing to a significant 29% increase over the past year, with earnings forecasted to grow by 16% annually. In this thriving environment, growth companies with substantial insider ownership can be particularly appealing as they often signify strong confidence from those closely involved in their operations.
Assessing Harrow (HROW) Valuation After US$8.1 Million In Recent Insider Stock Sales
Insider selling puts Harrow stock under the microscope Recent reports of Harrow (HROW) insiders selling US$8.1 million of stock over the past 3 months with no insider buying have sharpened attention on the company and its recent share price swings. See our latest analysis for Harrow. Harrow’s recent share price moves reflect this tension, with a 1 day share price return of 3.26% and 7 day return of 5.61% contrasting with a 90 day decline of 21.38% and year to date decline of 25.67%. At the...
What Harrow (HROW)'s New US$50 Million Senior Notes Offering Means For Shareholders
Harrow recently completed a private offering of US$50.0 million in 8.625% senior unsecured notes due 2030, issued at 100.25% of principal under the same indenture as its existing US$250.0 million 2030 notes and guaranteed by certain subsidiaries. The transaction, sold under Rule 144A and Regulation S, gives Harrow additional balance sheet flexibility to fund product launches, development projects, and future business development initiatives. Next, we’ll examine how this additional US$50...
A Major Investor Just Sold $7.8 Million in Harrow Stock -- Is This a Sell Signal?
This ophthalmic pharma specialist -- known for its compounded medications and royalty streams -- just reported a big insider sale.